Cell-free synthesis for the clinic: How Invitris is building a phage printer — Podovirus podcast
54 min

Cell-free synthesis for the clinic: How Invitris is building a phage printer

The conversation

Episode notes

Invitris founder Kilian Vogele explains how bacterial machinery can assemble phages outside living cells, and why making that process reliable took years of work. Listeners learn what the system can reveal about phage biology, where its limits appear, and how it could support a planned machine that produces phages from DNA.

Vogele reports that one cell-free system can produce phages targeting several bacterial hosts, although more distant hosts may require extra factors and membrane-dependent M13 does not work well.

Adding DNA for alternative tail fibers let the team broaden host range, but Vogele cautions that getting a genome into another species does not ensure it can function there.

For a future automated system, Vogele favors adapting established phage designs with selected parts, because assembling those parts is already possible while synthesizing large genomes remains a bottleneck.

Episode timeline

  • 0:00 Introducing Kilian Vogele and Invitris
  • 8:41 How bacterial machinery makes phages outside cells
  • 18:18 Why use one production system for different phages?
  • 24:03 Changing tail fibers and removing essential genes
  • 30:37 Research collaborations and the planned phage printer
  • 41:36 Why temperate phages can stay repressed in extracts

Transcript

AI-transcribed and edited for readability. May contain errors or omissions; check the recording for exact wording.

Select a word or timestamp to listen. Use arrow keys to move between words.

  1. Jessica Sacher

    Welcome everyone to the Podovirus Podcast. Welcome back. We're super excited today to be here with Kilian Vogele. He is founder of Invitris, and so this is a company making, cell-free phages, and we're gonna dive into how that's going, because many of us in the phage field have heard about this for a while. We know that rebooting phages from scratch is important for synthetic biology and all these AI-generated phages.

    We need the physical component to be able to actually bring them to life. And so that's why we really wanted to talk to Kilian about what their company is working on in this space. And I met you, Kilian, I think eight years ago at random when we both happened to be in Brussels visiting Jean-Paul Pirnay's phage making facility. And I remember he was like, these are these guys, Kilian and Quirin Emslander.

    I think you're co-founder, right? And yeah, and he was like, Oh, they're making like phages in a test tube. And we were just starting phage directory at the time, me and Jan. So that was just like such a cool chance meeting. And I think you just like, won iGEM or something, but you were just starting out with seeing if this technology could work. So welcome to the podcast.

    We also have Joe here, and so, yeah, let's kind of dive in. Maybe Kilian, you can, like, give us a bit of background of how you got into this. Like, take us back to 2018, or even if it was before.

  2. Kilian Vogele

    It was around that time, so actually also I kind of stumbled across phages by chance. So initially, I'm a physicist by background and I worked in the area of synthetic biology. And during my PhD, I wanted to build some stuff like, some artificial cells, so having some membranes which are growing and dividing. And when I had this, I saw, Okay, now I have a, like, bubbling membrane.

    And then I lose my genetic material to continue to grow this peptide vesicle. And I was wondering, like, how can I replicate DNA? And there I came basically across phages, because then phages inject their DNA into bacteria, replicate their DNA there. And yeah, then good to go. I had this, yeah, in vitro system, so like the cell-free system you already introduced, and yeah, basically I wanted to check, okay, can I use this cell-free system and a bacteriophage together for

    this DNA replication? And that was kind of the starting point of all the research. I started from there and it was like, not any medical question, or because I was new to this phage field. Actually, you kind of read a bit about what phages are, but you know, you didn't really have a grasp for it. And yeah, and that was like early 2018, when we got the chance to host like this, iGEM team, so basically in our laboratory, we got the chance to host

    a student team. There were 16 students who were all working together on one project for roughly a year. And I was part of it as a supervisor of that team. And yeah, we discussed several projects, and one was also like bacteriophages and making them cell-free. First, we were thinking, okay, rather thinking about making an engineering platform for genome engineering of bacteriophages cell-free. Because sometimes it's hard to bring the DNA after you modified it back to the bacteria. I mean, for E. coli, it's kind of easy, but some other like capsular bacteria, that's way harder.

    And that was kind of the starting point. And then early on, we luckily met Jean-Paul Pirnay at like an opening of a local bio lab in Munich from Jérôme and Rüdiger. And there, like, we also pitched him our idea, because, like, I mean, he has so much knowledge and overview over the whole field. And there he told us that it's even only great alone, just to make the phage cell-free, because it has a lot of advantages.

    Like you don't need the pathogenic bacteria, you have less, like impurities and like a lot of other advantages, which we didn't know before, because, like, we usually don't produce phages normally, and therefore we didn't know that this is a problem, also like not making phages for therapy. I mean, it's a difference if you want to make a phage in your lab just as a stock to store it away, or you really want to make it to give something to patients. And with this interaction with Jean-Paul, like, more and more became clear that it's like, really interesting to make cell-free bacteriophages for therapeutic use.

    And then we, like, also pivoted a bit in our project and really focused on that. Also to collect some phages, see how many different phages we can make in the cell-free system. Also like larger phages, smaller phages, also against different bacterial strains. And then I think we met shortly after the trip to Boston, where we presented all our results and had like, a really good time.

    Like several days where, like, the whole student team, like, presented everything, and yeah, everyone had a good time. And overall, we also were quite successful there. But then after that, we were thinking of how we should continue this project and also got this invitation from Jean-Paul to visit his lab, where we met you, and it was kind of our first touchpoints with, like, more senior phage scientists.

    I mean, we are just like starting off and we're happy to make like a plaque assay and stuff like that.

    And yeah, so it was really, really interesting. And from there, I mean, we then wanted to continue this project. And yeah, also like, we were thinking, how should we do that? So, because you're like a group of students, also some. I mean, I was also still doing my PhD. And how to continue this was quite… Yeah, then we had different ideas. And it's like, because some of them were still in their bachelor, some in the master's, so I mean, some of them actually also wanted to continue.

    And then we thought, like, Okay, let's try to make it in a kind of a startup direction.

  3. Jessica Sacher

    Cool.

  4. Kilian Vogele

    Because that's like, then we still can, like, try to bundle everything kind of together, still work like a bit in the lab. And also, like, doing stuff together to continue this. From that, basically, then Invitris came along some years ago.

  5. Jessica Sacher

    Yeah, amazing. That's such a cool origin and also crazy to imagine 16 students like productively working on one project. Like, I don't know how to do that yet, but like, that's so cool that that worked out like that. Like, how many of the 16 still work with you?

  6. Kilian Vogele

    Like, I think two are like, still like, like, connected to Invitris, also like, yeah, some like. I mean, they also want to do their PhD and everything, and like, I mean that makes sense to go.

    And I mean, time-wise, they're now like slowly finishing their PhDs, so let's see what will be the next step. But yeah, I mean, as I said, we were somewhere like in the second semester of their bachelor’s and they were also doing a really great job. And we also distributed all the tasks, like some masters teaching the bachelor students, having some teams, and yeah, that worked really nicely.

  7. Joe Campbell

    So the company is associated with the university. I mean, where are they getting their degrees from when they get their degrees?

  8. Kilian Vogele

    Yeah, so the nice thing was like my PI was giving us a lot of freedom. So I mean, he's in a synthetic biology group and kind of we were the only people working with phages there. But as a PhD student in Germany, you can like, also teach, like, supervise master theses and bachelor theses. And I mean, for sure, they went to their normal courses, so they could finish their studies normally.

    But they were like working with me as a working student or as a master thesis or some internships. There was some freedom from the university, so that was also quite, quite helpful to continue and stay together as a team.

  9. Joe Campbell

    Their degree comes from the same university yours came from?

  10. Kilian Vogele

    Yeah, exactly. We were all in the same lab of my former PI, Professor Simmel, and the degree was from the Technical University of Munich.

  11. Jessica Sacher

    Awesome.

  12. Joe Campbell

    I sort of thought it was probably like that, I just wanted to make sure.

  13. Jessica Sacher

    Yeah. Can we talk about cell-free phage production just from a beginner's point of view? For people who are wondering like they work with… Probably if they're listening to this, they maybe they work with phages, maybe they're just interested in phage therapy because we dive into that a lot. But what is it, what's happening, and how? Obviously, you can't tell us all your secrets, but how can you possibly make phages without a cell?

  14. Kilian Vogele

    So basically, you have three components which you need to make a phage cell-free. One component is the information where the phage is coming from, so basically the DNA. So it's like the building plan where everything is coming together. Then you need to have kind of the machines to produce the phage, which is like the ribosome and tRNA synthetases and everything which is in a normal bacterial cell.

    Together with some buffer where, like the energy mix is coming from, and also like the building blocks, everything comes together and makes this bacteriophage. So basically, to get all these three components, for the machine which makes the bacteriophage, so like, like the ribosomes and everything. We start with like a bacteria culture, so usually like a safe lab strain of, yeah, some well characterized bacteria.

    And we let them grow. We remove the cell wall, we remove the DNA so that we get like all the proteins inside the bacterial cell, which basically can, if you add some DNA, make new proteins. And we do some purifications and some tests. And if we get then all these enzyme like proteins out, we have also like a big mixture of all the different components.

    which the cell needs to run. You can imagine, like the fuel of the cell is like ATP, but we also have something to like regenerate ATP to let it run longer, which is also important for phages. And adding this together with some proper DNA, you can make any protein of choice, and if you add like a proper phage DNA, you can also make like a complete phage from that.

    So, it's really cool, like, like all the stuff which happens in a normal bacterial cell, just happens then in a big test tube. So you can imagine like we have taken, or like mimicking what's inside a bacterium, and making it happen in like a normal plastic tube, which has a larger volume, making way more phages in one, go, and yeah, there everything happens as a normal phage would do its program.

    And you just put everything together, store it at a constant temperature, and after four to eight hours, you get your sample out and your phages are ready to go.

  15. Joe Campbell

    Nice.

    Yeah, I was… Go ahead.

  16. Jessica Sacher

    And Yeah, go ahead, Joe.

  17. Joe Campbell

    I was just curious, cause that was many moons ago. I was in a lab that wanted to recreate yeast cell biology processes. And they just, we just grew yeast and put it in liquid nitrogen, and put the liquid nitrogen in a blender. And we just took what came out of that. And it would like transport proteins around the cell in the test tube, I mean, around different organelles of the cell in a test tube.

    So it sounds like you do something a little bit more complicated than that, but, I mean, it was fascinating that it really worked really well.

  18. Kilian Vogele

    Yeah, I think, like, also, you know, we also did some stuff on mammalian cells, not phages, but I mean, we also do other things. And yeah, for bacteria, I mean, the most important thing is, especially for phages, you need like a really high-quality cell-free system. Because for the phages, you need to make a lot of different proteins and they all have to build together and they are all in the right stoichiometry.

    And I mean, also loading the DNA into the phage head costs some energy. And as there's so much going on, you need a quite well-functioning system. I think that's really the key. Yeah, so that's the main tricky part, and also like the details on how you prepare the system. I think that's really the key. To like to make phages. Because in the beginning we also had some batches in which we couldn't produce any phages.

    And we were screening, like, I think, for three, four years to make, like a really well-established method to have this well expressing cell-free system.

  19. Jessica Sacher

    Yeah. I'm really curious, like, how general is it? How many kinds of phages can you make with one system? And like, are you using like the same base host soup for a lot of different phages, like beyond what would be able to infect that host in nature?

  20. Kilian Vogele

    So it works, quite nicely for like, a lot of different phages. So we made RNA phages, like normal, Caudoviridae, so those podo, sypho, Myoviridae, all kinds of different shapes. I would say, and that it worked quite well. We also were able to make like phages which are not coming from our host. So like, so, usually, if you say you want to have a phage against bacteria XYZ, the cell-free system can make it work, but I cannot guarantee for like each single phage.

    So, for example, the M13 phage. I think it's used quite often, and it's growing out of this membrane when it's replicating. And for example, this phage is not working in the cell-free system because it needs like the membrane to grow out. And even if you're mimicking some membrane parts, like with some lipid rafts in the cell-free system, it's not working really nicely.

    But like a bunch of different other phages, for example, work quite nicely. And also what's cool is like the closer… The cell-free system derived from that can make a lot of different phages without modification, also against other hosts, like in, for example, Klebsiella or some Pseudomonas species. Even if it's like not coming from these bacteria, this, initial host, so that's kind of quite a nice thing to see.

    For host bacteria that are further away. I would say there you have to make some tricks. So there we co-express, for example, some important proteins or factors to make this work. Not all of them are working always out of the box, but you can, like with some dedicated searches, also find the tricks to make it run. And the cool thing about the cell-free system is like, Okay, you know, these four proteins are missing to make this particular phage from, let's say staph or whatever.

    And you don't put in the purified proteins, but you just put in the DNA encoding for the proteins. So you throw in the phage DNA plus some more DNA you ordered from your favorite DNA vendor and everything then works together, which is quite nice.

  21. Jessica Sacher

    That's really cool. Nice, so I guess, yeah. It might illuminate some… Like, as you try things and see which phages fail. You might kind of, like, learn a bunch about the biology of what makes a phage assemblable that we probably still don't know about most phages.

  22. Joe Campbell

    So do you know? I don't know. This probably isn't that easy to do, but have you looked, you know… A lot of people are now looking into what genes are expressed and they have been for a while. What genes are expressed early, late and in the middle of an infection? Have you looked at that? Are you seeing, like, when you first introduce the DNA into the gammish, do the early genes get expressed?

    And then only later, the middle and ultimately the later ones? Or

  23. Kilian Vogele

    Yeah, so we did exactly some of these experiments, like with mass spectrometry. So we threw in the phage DNA. Took some samples over the time and sent them, to mass spectrometry. And we really saw that you got like this early, late and middle genes, exactly as predicted for this particular phage. Because, I mean, for a test case, we take a characterized phage, so we know what to expect, and we could also replicate that quite nicely.

    Also nice, we were also able to see some prior hypothetical proteins expressed. We could show that these hypothetical proteins were somewhere in our soup. We don't know what they're doing, but they were like, also expressed, so they’re not just hypothetical protein, but you could confirm the expression of these proteins. What I have to say is, for example, a T7 phage replicates like within 20 minutes in the bacterial cell, or like 18 or something.

    In the cell-free system, it takes a bit longer till you get the first phage. So like after three to four hours, and you get like the final titer after 6 hours. So everything is a bit slower because the cell-free system is also ten times less dense than a bacterial cell. And in a bacterial cell, if you see some videos where like, walking protein, like you see, like quite an empty void, but it's not the case. It's like packed, like super densely, and the cell-free system is a little bit less packed. And therefore everything is a bit slower. But therefore, you also get like better time resolution if you want to check for early, late and middle genes, which is also quite nice.

  24. Jessica Sacher

    Yeah, so cool. So in terms of the why you might wanna make cell-free, like you touched on, obviously the phage therapy case when we want it to be less toxic, so we don't have to use anything pathogenic to make the phage. Then we probably don't have to spend so many resources on getting rid of things like endotoxin. What other reasons have you come to find are like reasons to use the cell-free system over the natural system?

  25. Kilian Vogele

    Yeah, I think like, like. A lot of points are like having also no prophages, for example. Because sometimes, as I think, it's really hard to purify your phage from the prophage because they're quite similar. So it's a bit harder. And then, well, for endotoxins, you can, like, use some columns. You hope that you don't lose too much phages, but That's a different story. So like endotoxins, we also have a lower amount. But overall, I think also for the more like industrial perspective, or like pharma perspective, it's quite nice to have like one system to make a lot of different phages.

    Because, like, just changing the input you have and you get a different phage out. And you don't have to, like, start from your bacteria again to remove some toxic genes, some unwanted genes to make, like, like a pure production strain and just having like the system. You can produce it like in a huge batch, like freeze it, just taking a fraction of it out, making your production run for your phage X, then taking another batch out of the freezer, making batch I and so on.

    And therefore, like, you also have like a lot of synergistic effects to make, hopefully, phage therapy like more accessible and also like, hopefully easier to use. I mean, there's this concept of a phage BEAM, also from Jean-Paul Pirnay,

  26. Jessica Sacher

    I was gonna ask you about that.

  27. Kilian Vogele

    Oh yeah, sorry, then I don't know,

  28. Jessica Sacher

    Oh no, go ahead, yeah, like Jean-Paul's, all his sci-fi writings, and like that phage therapy 2035 paper. I think your technology is like a key part of that coming true.

  29. Joe Campbell

    I have a question about the sort of extract, or “gammish,” as I called it earlier.

  30. Kilian Vogele

    Sure.

  31. Joe Campbell

    How much bacterial DNA is in there? Is there any effort to reduce the amount of bacterial DNA, or do you have the bacterial DNA in the gammish along with the phage DNA?

  32. Kilian Vogele

    And so we have like really low trace amounts and there are some steps included in the process where you get rid of the DNA. So, like, we checked with some qPCR and got like really low amounts, which were also like fine. We checked with some German regulatory authorities. And

  33. Joe Campbell

    Regulatory people? Maybe Jeff was gonna get to that also, but an obvious question, but so, you have, I guess I don't know this. But have phages that have been made in your method been used therapeutically? And if so, what countries and what have the regulators said about this?

  34. Kilian Vogele

    Unfortunately, the cell-free phages are not used yet for the treatment of patients. We were in conversations with the German regulators, but also with some from people from Belgium. The main things like, and where we’re still in discussions like we need to show that our phages produced cell-free are basically the same as produced in bacteria. And to run some tests there and to see like if this is… To have proof points that it is like that.

    And then I think there can be some use cases for this cell-free production. But I mean…

    Yeah, and, um, the other part is like, I mean, in Belgium you have like this magistral preparation, where you have to show afterwards that your phage is really good and clean and everything. But if you want to go into a clinical trial setting, you have this GMP production where you have to like produce like your batch of phages in a, um, quite strict manner, and it like takes a lot of time and expertise.

    But we are also already in the phase where we have this, like tech transfer to a company that would do like a GMP production of our cell-free system to like to bring our cell-free phages to patients. Hopefully soon.

  35. Joe Campbell

    Did regulators express that they want any tests to be done on the phages that they don't require to be done on phages that are made the old-fashioned way by bacteria? Or, I mean, I guess what I'm asking is, do they have some additional concern? You know, I mean, I know they haven't done it yet, but in the conversations you've had, have they asked for tests beyond what they asked for the phages that are made?

    Sort of the old-fashioned way?

  36. Kilian Vogele

    I think just beyond, what the conventional phage would be tested against was about, like the mutation rate of the single phages. So because, like, I mean, the DNA, so some phages also replicate the DNA in the cell-free system. And also like, if the mutation rate changes from a conventionally produced phage. We also have some methods to in vitro amplify the DNA.

    And if you do the calculations with the enzymes and everything, and you know the error rates of your normal phage polymerase, which is rather high compared to like some other proteins, usually, it should be lower. But I mean, there we need to also prove this or show this first to our people.

  37. Jessica Sacher

    Hm, got it, yeah, and there are so many different directions it could go. But like, it just sounds so cool that you can add exogenous DNA so easily to start. Like that would open up a whole window, or just like a whole bunch of possibilities with engineering the phage. And I feel like I didn't originally appreciate that. But like, instead of having to, you know, clone in, or, like, express a plasmid in your host cell, or, you know, try and get that extra DNA to make

    even a mutation in a phage, like you said, you can just print extra genes, basically, probably get them made by Twist or something and throw that in. Like, have you explored making phage mutations in that way? Because it seems just like such a nice platform for that.

  38. Kilian Vogele

    Yeah, I think like for the cell-free system, where we did a lot is like, I mean, can you imagine like a phage, like a Lego set, which builds itself together just by putting all the parts on the table? Kind of, right? And if you mix in some other parts, like which are similar enough, they also build into the phage. And in the cell-free system, we are able to, like, mix a lot of different parts additionally together.

    So to be more concrete, for example, the tail fibers of the phage, which are like responsible for checking which bacteria they want to attack and which ones not to. You can also mix in like a bunch of different other tail fibers to make some phages, which you get out of cell-free, which can attack also like different hosts, which were not initially able to. So we were even able to show that we can, like, cross species with that.

    I mean, you can do that to a certain extent, because, I mean, also the phage genome had to be read by the bacteria to put it in. But entering the genome, it was possible there just by adding some additional like, like piece of DNA for a different tail fiber and then even cross like species with that, and also like adding a lot of different tail fibers.

    You can make like a phage with a larger host range than initially.

    You can, like, also genome engineer the phages, of course, which is also working quite nicely because you can use all the usual like in vitro assembly tools and also selection tools. And you don't have the transformation step, so that's like a big plus, I guess. And with that, we were also like, able to like genome engineer phages. And we can also do stuff which you can not usually do.

    So we deleted some essential genes to make a phage which you can produce cell-free, which kills the bacteria but does not amplify.

    And just to see if we can.

    And that also worked quite nicely. So, yeah, you can also, like, I think you can use it as a tool for like research to see, like, what does this gene do? And like switching off some of them. But you can also like, think about like therapeutic uses, or to have like a faster screening tool. So, for example, having, like, a phage without a tail fiber and then just adding like all the different like tail fibers in the solution. And then checking on a spot assay if you see something or not.

  39. Jessica Sacher

    Yeah. Related to that, have you tried just adding like genomes from multiple phages and seeing if you get some naturally occurring frankenphages that way? Like, almost like an Appelmans protocol, but, I don't know, more likely to work, cause they're all just really right in there. And to try and kind of have directed evolution just take place and see what mixes and matches you get.

  40. Kilian Vogele

    We tried there a bit around, but like, kind of stopped at one point because I think they inhibit each other sometimes. And if the Lego kind of self-assembled Lego blocks are mixing too wrongly, I think then they might inhibit each other. Like if they are orthogonal enough, you get these two separate phage species which are not mixing, and then it works also fine. But if they mix too weirdly often, I mean, if they are close enough for each other, then it works.

    But then it's like also just exchanging whatever three proteins, and then you see the same effect. But if you mix too widely, there's I guess there will be too much inhibition of the assembly, or, I mean, there are also some other like self-inhibiting effects.

  41. Joe Campbell

    I’d suggest, perhaps a simpler experiment, like, you know, many years ago, people isolated T4 phages with TS mutants in various genes. So you could take a very simple experiment of taking two different pieces of DNA, both of which had a different TS mutant. And if you put them in separately, of course, you would just get out things that were temperature sensitive.

    But you could imagine that if you put them in together into your cell-free extract, if you got recombination, sometimes you would get a piece of DNA that had recombined. So it had the wild-type copy of both genes and you would have a phage that wasn't temperature sensitive. I mean, I guess that might be, to my mind, a simpler way of… Because, I mean, I guess there could be incompatibility.

    But those genomes would only be different from each other at maybe just one base in two different genes. So they'd be very similar and they should be perfectly homologous, obviously, so recombination should like happen quite readily. I mean, this is how Seymour Benzer did this stuff many years ago, I mean, and sort of all the classic phage stuff. But I mean, I guess I wonder if you just started with that, that might be an easy bar to clear.

    And then, you know, you'd be confident. Like, yes, we get good recombination. Hey, I'm talking too much.

  42. Jessica Sacher

    That's cool.

  43. Joe Campbell

    But you get the point that it seems like that would be a very simple experiment. Like you take gene X of T4 and T4 gene Y and throw both those DNAs in there and you get something out that's not T4.

  44. Kilian Vogele

    Yeah, I think that's a really, really nice suggestion. So this we haven't done so far. I think also maybe we would have to make a specialized cell-free system for like homologous recombination, because it's a little bit suppressed in the system we usually have, because we don't want to have some of the proteins interacting with the DNA and weird stuff.

    But yeah, I think it wouldn't be too hard to make a special system which could do more homologous recombination and then test this with T4.

  45. Jessica Sacher

    So cool. So where are you at with in regards to, like, interaction with the outside world with your system? Like, is it a kit that somebody can buy in a research lab, or are you going to be supplying phages for a clinical trial? Like, are you gonna make a drug? What kind of direction is Invitris wanting to go?

  46. Kilian Vogele

    So concerning the kits, so we have with some partner labs, some like kind of collaborations, where we supply them with the system. For us, I think it's like, always important that we can, like, work together on their problems. So like, because for sure, like, if you get the kit, you would get like also some example phages to test and to see: can you run it in your lab or not?

    Whatever weird stuff is happening and the experiments are not working out, so that we can at least troubleshoot, like with a positive control. But I think what we also want is like learning from what they do and also giving them like feedback or like helping them troubleshoot to come to the solution. Like, kind of more together, I think that's really important for us to, like,

    have both parties kind of get something from that, because we don't want to just like, like, sell this kit like a normal, like, ordinary commodity. And besides that, we're also like, working currently, like in the direction of like, Jean-Paul's phage BEAM, as we discussed before.

    Maybe I will shortly explain what this machine is and then what part we try to build.

    So, how do I say it correctly? The idea would be something like you have a bacterial infection. You put this into a machine and after a time, a certain time, you get a phage cocktail out, give it to the patient and the patient is hopefully healed. I mean, and there are a lot of steps happening in between, like some AI finds out what phage you should use.

    The phage needs to be produced somehow and then also like purified and given to the patient. And with our cell-free system, I think it's like a really good thing to use for the production of the phages within such an automatic pipeline. And for that, we got like an ERC grant, where we currently develop like something like that, where you basically put in some DNA and then get out some phage-related particle.

    And kind of in as automated way as possible. So basically having something like a phage printer, which would be part of this phage BEAM. Yeah, we’re currently also developing that, and there are a lot of moving parts as well. So, I mean, you have to have the input materials, like the cell-free system, which you also need to have in a certain quality.

    Like this, yeah, GMP parts. But also like, having like a machine which could, like, put everything together and give you the phages. So like, kind of a printer. And that's also what we’re currently, like, working on. And hopefully with that, let's say in, yeah, some years, or like in the future, a hospital would have this instrument on site. You get like a patient sample, you know, it's like this certain Staph aureus or something, and then you tell the machine which particle to produce, and then

    it runs and gives you something which you can use in the patient. I think that's, what we're currently like, also developing.

  47. Jessica Sacher

    Yeah, so cool. And I feel like the whole AI-generated phages and we've interviewed Samuel and Claudia about that work at the Arc Institute. But I think it just dovetails well. And I wonder what you think about it. Because I could see that phage BEAM system involving a component where the, you know, the bacterial strain has been assessed to be something. And it's like, well, do we use a natural phage genome or do we make one up right now?

    That should work against it? Either way, your kind of system would theoretically be able to build it. Maybe like, do you think that that piece, like the AI generation of a new phage, is required for this type of system? Or like, how much of an important piece is that? Or could your system work with, just like constraining it to choosing among a set of phages known to work?

    Like, what do you think about all that?

  48. Kilian Vogele

    So I think, first of all, it's really cool what they did. So, like, like having like a system to make artificial phages, which were never there before. So I mean, that's really amazing. And I think also like parts of it will be, yeah, like, used, like, hopefully there somehow. Currently, I think like we don't need to have like the whole phage, always completely new. So if you say like, you have a certain subset of really well-functioning phages, and then just exchanging like smaller parts, like the tail fibers or certain anti-defense mechanisms.

    So, like I mentioned, like, you have like a kind of a breadboard, where you’re just putting stuff together to make the phage, which like targets your pathogen the best. So, for example, you see this is a certain CRISPR mechanism which this bacterium has. So you need this cassette for making the phage resistant to that. And if you see, ah, I need this tail fiber for this phage, for this bacterium, I pick this tail fiber out of my box.

    And you don't need all the proteins like newly. So, I mean, for example, if you have a stable capsid part, maybe like having three, four, five different of these chassis there. You can, I think, go and check this out and not have to make it completely from scratch. Because I think it's also faster, because, I mean, they use rather small phages to do all their part.

    Not, I think because of the limitation of the model, but like to make this DNA is like the limiting factor. And I think due to that, I think also like to having like this picking from like a larger set and then putting all the parts together. I think that would be also more like you can make it faster and also like you don't have to say like, ah, in ten years we can synthesize 200 kb genomes in 2 hours or something. But you can already do like stitching parts together now, so I think that's also quite helpful.

  49. Joe Campbell

    Just curious, how high a titer have you been able to achieve? That's my first question, and then I have a follow-up.

  50. Kilian Vogele

    And that varies a bit on the phage, so on average, the smaller the phage, the higher the titer is. So like with a really tiny phage, like an RNA phage, this MS2, you got like around ten to the thirteen, fourteen, but I mean, it just has four genes, so it’s, like, not too big. With some polyvalent phages there, we’re around ten to the twelve-ish, and then like, yeah, like ten to the eleven, ten to the ten-ish on some other phages.

    So it varies a bit on the size. And that's because, like, the more proteins you need to produce, the more metabolic load you put on your system. And therefore, you’re exhausting your ATP, or like your fuel of your system a bit. So therefore, you have to be a bit careful, about the size.

  51. Joe Campbell

    And I guess the follow-up question to that is, I mean, do you know that? I assume? I mean, you're getting ten to the 13th, with the smaller phages, you're getting that many phage particles, but I guess what I'm asking is how many phage particles do you get that don't infect? Do you have any idea of whether you're getting a large number of phage particles

    that, like, if you count phage particles under a microscope or something and try to figure out how many phage particles you have, and then you know, and then you count PFUs. Is it close to one to one? I mean, I guess I'm partly asking, because, you know, I would be worried if you were getting like ten to the 13th titer of phage, but you're actually getting ten to the 15th phage particles.

    Then you might start inducing immunity. And, you know, in the patient, and that would be bad. So, anyway, that's the question: do you have an idea? When you have ten to the 13th PFUs, do you have roughly ten to the 13th phage particles?

  52. Kilian Vogele

    And so we did some electron microscopy imaging of like conventionally produced phages and cell-free-produced phages and compared these. And there the numbers of like empty versus like filled phages look quite similar, so there were not like too much variation. I didn't check it for all the phages because, I mean,

  53. Joe Campbell

    That's good.

  54. Kilian Vogele

    but like for the test setting when we initially had this question as well, it looked fairly similar, actually.

  55. Jessica Sacher

    That's great. Do you have a way to monitor? Like, cause it sounds like the limiting factor is like ATP, polymerases, like energy and machines. Can you monitor in your reaction? Like, as those are getting depleted, and then like, add them back to keep the process going longer, or to, like, extend it so there isn't a maximum?

  56. Kilian Vogele

    So like we did some like extension experiments, so like the normal experiment is just to mix everything together, put it into whatever incubation chamber and wait. But we also had a system where we have like a source outside which could feed like back into the system. And there you can also reach like higher titers. Didn't work like infinitely. I mean, at one point there is some limit we’re not completely sure about yet.

    Like, I mean, we have some hypotheses about what could be the limiting factor in the end, which cannot be depleted or is always depleting. I mean, one part is that at one point the DNA is all gone, for example, and because it should be all in the phage particles. But yeah, there are also some other factors which don’t give you an infinite amount of phage particles.

    But, yeah, you can, like, increase the titer, like around two logs, roughly by like having like an outside source where you add like stuff to the system and also letting stuff out, right? That's, the next thing, because like you kind of generate, let's say, yeah, trash kind of, which you have to get rid of. So like changes of like some metabolites, which would inhibit the system, and you just also get rid of these, which is, yeah, also can be done.

  57. Joe Campbell

    So I'm gonna ask you an impractical, geeky biology question that I'm fascinated by. But if you put, say, lambda DNA or whatever, you pick your favorite temperate phage, and I guess for a lot of people it's lambda, but you put lambda or some other temperate phage into your extract, does it think it should be making lysogens and repress, and not make phage particles, and establish repression, or does it make a bunch of phage particles and think that it's supposed to be going lytic?

  58. Kilian Vogele

    So what we saw like most usually on the phages, it should be suppressed, so so on average, they think they are in the lysogenic cycle. And

  59. Joe Campbell

    I see.

  60. Kilian Vogele

    you have to do something to make it like think it's in the lytic cycle to make these phages. I mean, every phage is individual, as I guess you also know.

    But on average we saw that trend.

  61. Joe Campbell

    Right, but I guess, yeah, so I guess, I mean, it would be really interesting to me if that's the case. And then if you put in a phage that does, you know, a lambda that has mutated for cI, the repressor gene, then it, then it just goes fine. Or,

  62. Kilian Vogele

    Yeah, so then if you like change something like we did some mutation in the like repressing region, and then like we saw, like, then it worked again. So that's also,

  63. Jessica Sacher

    So cool.

  64. Kilian Vogele

    I mean, but you have to know like if it's an unknown phage, I mean, for the lambda phage, everyone knows everything.

    There’s a lot in the papers, but some random phage you get like there, you have to also check and see what's close by.

  65. Joe Campbell

    I mean, I wonder, like, you know, people have been thinking about, like, what influences whether you make a lysogen or go lytic for years. And this is like one of the things that people still argue about, you know, phage geeks still argue about the lysis–lysogeny decision. And I wonder, like, if you, I don't know, like, you know, just a simple experiment of if we have the extract at maximum concentration.

    Does it favor the lytic pathway? And if you dilute it and get a less concentrated extract, I guess you probably are having more problems getting the phages to work. But it would be, you know, really interesting to see, like how the protein concentrations in the extract affect, whether in vitro you get lytic or lysogenic.

    I don't know exactly what you would learn, but, you know, this is one of these things that people have been arguing about since they discovered that lambda could do one or the other.

  66. Kilian Vogele

    Yeah, I think like, maybe more important could also be like the state of the cells when we make the cell-free system. So I mean, we remove a lot of like the smaller metabolite parts. But still, like, the composition of proteins is the composition of a happy cell. I would say so. It depends a bit, because, my random guess would be if the cells are happy,

    I mean, then it can go on more to the lytic cycle, because I mean, then there's everything there to replicate happily and make a lot of new phages. But for the cell-free system, it seems like, yeah, but as you said, maybe it's the protein content. Yeah, but there we are a little bit limited in the ability to play around, because if you concentrate the cell-free system too much, you don't get like protein expression nicely anymore.

    So it's like there the degree of freedom to play around is a bit limited. I would say,

  67. Joe Campbell

    So I sort of naively have assumed during this conversation that you make your extracts from things that are basically growing in log phase, mid-log. You don't wait till they're saturated. Is that correct?

  68. Kilian Vogele

    Yeah, so, and you can do even both. So I know also like other people who like harvest them in the stationary phase, more or less, but we go like earlier. So, oh well, so far, it works there the best. But it's also possible to go all kinds of different phases, even in the starvation phase, where like, the bacteria start to eat each other.

  69. Jessica Sacher

    Have you tried introducing a library of different phages to see which ones assemble better, or like a mutant library or something into your system? Hm,

  70. Kilian Vogele

    Yeah, so we tried, like, for example, like tail fiber mutants to see like which is the best working one. So I mean, it's quite straightforward, and then you can like, check which one is working well. There are also different like options. I mean, you can do it like genetically, putting all these mixtures together, throw it in the cell-free and then just do a plaque assay and pick some plaques and to see which are working and which are not.

    But you can also like do some assays with like microfluidics. So you can make like a lot of different phage particles in like a confined environment. And then like adding bacteria to see whether it works or not, and then looking for the working phages. So that's also a possibility which you can use with the cell-free and some large-scale screening capabilities. Because there you get like ten to the eight, nine particles you can sort within one experiment, even a bit more, if you have more patience.

  71. Jessica Sacher

    So, I know that you guys wanna expand towards phage therapy more. And we talked about your partners on the kit side and research partners. But do you also want clinical partners yet? Or where are you kind of in that timeline?

  72. Kilian Vogele

    So there right now we’re, checking the indication, like which one would be the one to go for the first clinical trial. But I think it's still confidential, I don't know.

  73. Jessica Sacher

    Okay, yeah, and yeah, just meaning like, can people help you? Or like, do you want, like, some infectious disease doctors to reach out because they have patients? Or they wanna start a clinical trial and need a source of phages? Like, can you be the manufacturer yet? Or are we upstream of that? You think,

  74. Kilian Vogele

    I think we're like, maybe a little bit away from that. So if we have this machine ready, like this phage particle printer, I think then it would be like, yeah, like, then I guess we also do a lot of outreach to see, like, who wants to work together. So, but like, we have to finish, all those building parts first, doing like one step after the other.

  75. Jessica Sacher

    Yeah, yeah, and like, in terms of the scale, we talked about, like how many phages you can make in a batch, but can you, like… I assume that’s—well, actually, I don't know if it was PFU per mL or PFU total, but can you make enough for, like, a clinical trial? If you decided you were ready to, like, physically make enough volume and enough phages for that many doses?

  76. Kilian Vogele

    Yeah, so like, there are two parts, uh, to this question. So one is like to make the cell-free system like in larger quantities. And there currently we are with this partner and this tech transfer process. And also like scaled up so that we have like the initial starting part around like ten liters. But, um, for the reaction itself, so in this phage printer, the idea is to have rather like smaller volumes, so that you make more or less enough material for one patient.

    But in principle, also like you can. So we didn't make like a large, like a really large batch yet. And because, I mean, that also costs some money and everything. But it should be also possible to create like a larger batch. If you say like, you go for a clinical phase one, two A trial or something.

  77. Jessica Sacher

    Okay, yeah. So the scale is not the hang up. You're just kind of making sure it works reliably and that you can prove to the regulators that it's the same and things like that. But otherwise, seems like a lot of stuff's figured out. Very cool. Do you have any other burning questions, Joe?

  78. Joe Campbell

    No, I think I've, you know, I'm not shy about asking my questions, I gotta admit, but it was fun talking to you.

  79. Jessica Sacher

    Yeah, this is so cool. So what can the phage community help you with? Or any listeners? What are you kind of looking for? Are you guys hiring? Are you guys expanding? Do you need more partners to try your kits? Can people order the kits? If they email you, how does that work? What do you need?

  80. Kilian Vogele

    Yeah. I think like, if you email Invitris for sure, like there's a way to have a conversation and check out, like, how to do something together. I think that's the case. And we're always happy to talk with people from the community, to see if they have a cool or crazy project. I mean, like, expanding your knowledge is always like, important, yeah, and I hope like down the line also at one point, like going more and more to clinicians.

    And also like, like having this in the direction of like a clinical trial, even if it's a little bit down the line yet for us. But yeah, then I think it would be also really interesting if someone like in a year or so hears this podcast, then, yeah, maybe contact us.

  81. Jessica Sacher

    Yeah, and like all the exotic phages you could probably make, like, I bet a lot of people are limited in what company they might start, or like disease they might try to treat. Because we just don't know a lot about how to make phages against that host. But if you are able to kind of expand that, I think that's really, like… This is just such a foundational technology to kind of go in so many directions.

    So I hope the phage community flocks to you to talk about how to do that. Very cool.

  82. Kilian Vogele

    At conferences, I'm also, like, happy to chat, always.

  83. Jessica Sacher

    Yeah, which conferences are you going to this year? Any phage ones, or other?

  84. Kilian Vogele

    Yeah, I guess to the Viruses of Microbes in Prague. I mean, it's not that far from Munich. So, yeah.

  85. Jessica Sacher

    Yeah, that's perfect, that one, we gotta advertise that. We don't have to, but we could. Viruses of Microbes. Are you going, Joe?

    Yeah, in Prague, July, when is it? July something?

  86. Joe Campbell

    Sixth through tenth, I think.

  87. Jessica Sacher

    To the tenth? Okay, you can meet Kilian there and Joe. Hm.

  88. Kilian Vogele

    Hope, like, we can meet each other.

  89. Joe Campbell

    We can, we meet. Yeah, every two years we'll meet at, Viruses of Microbes.

  90. Jessica Sacher

    Yeah. Well, thank you so much, Kilian, for sharing. And I'm really happy we got to dive into the nitty gritty and figure out, like, physically, what is happening. I feel like I have a good picture and I just wanna go order your kit now so I can ask all my phage questions. So expect some emails from me and maybe some more of our listeners.

  91. Kilian Vogele

    Also, thanks for letting me show the cell-free technology to a broader audience, so really happy to share all this.

    So it's a lot…

  92. Jessica Sacher

    no problem. And do you have any papers out that people can look for? We'll put them in the show notes, but have you published on any of this?

  93. Kilian Vogele

    only some of the earlier stuff. Like, because it was like, yeah, when you start a company, then you're more into the patents. And unfortunately don't have the time to publish everything.

  94. Jessica Sacher

    Okay. Well, we'll put some early stuff.

  95. Kilian Vogele

    Should have taken the time to… Sorry, I don't know.

  96. Jessica Sacher

    No, I’ll look for it.

    But good to know that it exists. And so if people wanna kind of, like, find out more and read more… Cool. Well, thanks, Kilian. Have a great rest of your week and good night. I guess it's night in Germany.

  97. Kilian Vogele

    Have a good start into your day, and all the best. Thanks a lot.

    Bye.

  98. Jessica Sacher

    Thank you.

  99. Joe Campbell

    Bye.

  100. Jessica Sacher

    Bye.